InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Signs CDMO Agreement for Oral Lucid-MS in Phase 2 MS Trial
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has signed an agreement with a leading contract development and manufacturing organization to produce an oral formulation of Lucid-MS for the company’s upcoming Phase 2 clinical trial. The trial will evaluate Lucid-MS as a potential treatment to help restore mobility in people with multiple sclerosis (MS), building on a decade of…